Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency

被引:119
作者
Colao, A
Di Somma, C
Cuocolo, A
Spinelli, L
Tedesco, N
Pivonello, R
Bonaduce, D
Salvatore, M
Lombardi, G
机构
[1] Univ Naples Federico II, Dept Mol & Clin Endocrinol & Oncol, Nucl Med Ctr, Natl Res Council, I-80131 Naples, Italy
[2] Univ Naples Federico II, Dept Biomorphol & Funct Sci, I-80131 Naples, Italy
[3] Univ Naples Federico II, Dept Internal Med 1, I-80131 Naples, Italy
[4] Sci Inst Res & Cure Neuromed, Pozzilli, Italy
关键词
D O I
10.1210/jc.86.5.1874
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adult GH deficiency (GHD) is associated with increased cardiovascular morbidity and mortality due to unfavorable lipid profile, hyperfibrinogenemia, and impairment of cardiac performance. This prospective controlled cohort study evaluated the effects of 12-month GH replacement on lipid profile, fibrinogen levels, cardiac mass by echocardiography, and performance by equilibrium radionuclide angiography. To this end we studied 20 patients (11 men and 9 women, aged 19-40 yr), 10 with childhood-onset (co-) and 10 with adult-onset (ao-) disease, and 20 sex- and age-matched healthy subjects. At study entry, insulin-like growth factor I (IGF-I; P < 0.0001) and high density lipoprotein (HDL) cholesterol (P < 0.0001) levels, left ventricular mass index (LVMi; P < 0.0001), ejection fraction (LVEF) at rest (P = 0.001) and at peak exercise (P < 0.0001), peak ejection rate (P = 0.005), and exercise duration (P < 0.0001) and capacity (P = 0.002) were lower, whereas total cholesterol (P = 0.02), triglycerides (P = 0.003), and fibrinogen (P = 0.005) levels were higher in patients than in controls. After 12 months, increases in IGF-I (P <less than> 0.0001) and HDL cholesterol levels (P = 0.04), LVMi (P < 0.0001), LVEF at peak exercise (P < 0.0001), and exercise duration (P = 0.009) and capacity (P = 0.003) and decreases in total cholesterol (P <less than> 0.0001),low density lipoprotein cholesterol (P < 0.0001), triglycerides (P < 0.0001), and fibrinogen (P = 0.01) levels were found in all patients, without any difference between co- and ao-GHD. At the end of treatment, however, total cholesterol, triglycerides, and fibrinogen levels were still higher, and HDL cholesterol levels, IGF-I levels, and LVEF at rest and at peak exercise were lower in patients than in controls. In conclusion, GH replacement for 12 months significantly improved lipid profile, decreased fibrinogen levels, and increased LVMi and LVEF in young adults with co- or ao-GHD. However, lipid profile, fibrinogen levels, and systolic function remained abnormal compared with those in age- and sex-matched controls, suggesting that a longer period of GH replacement is necessary to normalize cardiovascular parameters and reverse the cardiovascular risk of these patients.
引用
收藏
页码:1874 / 1881
页数:8
相关论文
共 45 条
  • [1] Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone plus arginine as provocative tests for the diagnosis of GH deficiency in adults
    Aimaretti, G
    Corneli, G
    Razzore, P
    Bellone, S
    Baffoni, C
    Arvat, E
    Camanni, F
    Ghigo, E
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (05) : 1615 - 1618
  • [2] BODY-COMPOSITION, BONE METABOLISM, AND HEART STRUCTURE AND FUNCTION IN GROWTH-HORMONE (GH)DEFICIENT ADULTS BEFORE AND AFTER GH REPLACEMENT THERAPY AT LOW-DOSES
    AMATO, G
    CARELLA, C
    FAZIO, S
    LAMONTAGNA, G
    CITTADINI, A
    SABATINI, D
    MARCIANOMONE, C
    SACCA, L
    BELLASTELLA, A
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (06) : 1671 - 1676
  • [3] Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment
    Attanasio, AF
    Lamberts, SWJ
    Matranga, AMC
    Birkett, MA
    Bates, PC
    Valk, NK
    Hilsted, J
    Bengtsson, BA
    Strasburger, CJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (01) : 82 - 88
  • [4] The effect of hypopituitarism on life expectancy
    Bates, AS
    VantHoff, W
    Jones, PJ
    Clayton, RN
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (03) : 1169 - 1172
  • [5] Cardiovascular disease and risk factors in adults with hypopituitarism
    Beshyah, SA
    Johnston, DG
    [J]. CLINICAL ENDOCRINOLOGY, 1999, 50 (01) : 1 - 15
  • [6] CARDIOVASCULAR EFFECTS OF PROLONGED GROWTH-HORMONE REPLACEMENT IN ADULTS
    BESHYAH, SA
    SHAHI, M
    FOALE, R
    JOHNSTON, DG
    [J]. JOURNAL OF INTERNAL MEDICINE, 1995, 237 (01) : 35 - 42
  • [7] Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency - A double-blind, placebo-controlled study
    Boger, RH
    Skamira, C
    BodeBoger, SM
    Brabant, G
    Muhlen, AVZ
    Frolich, JC
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (12) : 2706 - 2713
  • [8] EFFECTS OF AGING ON ASYNCHRONOUS LEFT-VENTRICULAR REGIONAL FUNCTION AND GLOBAL VENTRICULAR FILLING IN NORMAL HUMAN-SUBJECTS
    BONOW, RO
    VITALE, DF
    BACHARACH, SL
    MARON, BJ
    GREEN, MV
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1988, 11 (01) : 50 - 58
  • [9] Increased cerebrovascular mortality in patients with hypopituitarism
    Bulow, B
    Hagmar, L
    Mikoczy, Z
    Nordstrom, CH
    Erfurth, EM
    [J]. CLINICAL ENDOCRINOLOGY, 1997, 46 (01) : 75 - 81
  • [10] CAIDAHL K, 1994, CLIN ENDOCRINOL, V40, P393